First shipment of J&J vaccine jabs to arrive on July 19 — DOH | Inquirer News
Pfizer, Sinovac doses also set to arrive

First shipment of J&J vaccine jabs to arrive on July 19 — DOH

/ 12:40 PM July 12, 2021

MANILA, Philippines — Some 3.2 million doses of the COVID-19 vaccine developed by the United States-based Johnson & Johnson’s Janssen, a single-shot jab, will arrive in the country on July 19, an official of the Department of Health (DOH) said Monday.


DOH Undersecretary Myrna Cabotaje said that the J&J vaccine doses will be part of the 16 million vaccine shots from different brands that have arrived or will arrive on different dates this month, among them the six million doses of Sinovac vaccine and Pfizer doses.

“Yung ating Pfizer na 562,000 doses arriving on July 19, tapos another (Pfizer) on July 26, 375,000 [doses],” she said in a Laging Handa briefing.


(Our 562,000 doses of Pfizer will be arriving on July 19 and then another 375,000 doses on July 26.)

“About 16 million ang dadating this July, kasama po yung mga dumating na,” she added.

(We will have 16 million doses this July, including those that have already arrived.)

Earlier, the Philippines received a total of three million doses of AstraZeneca’s vaccine — one million as a donation from Japan and the rest from the COVAX facility.

Some 170,000 doses of Russia’s Sputnik V vaccine procured by the government have also been delivered last week.

So far, over 3.5 million individuals have been fully vaccinated. More than 9.6 million are still awaiting their second required shot, according to Cabotaje.

In total, the Philippines has so far administered over 13 million doses of COVID-19 vaccines.

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: coronavirus Philippines, coronavirus vaccines, J&J
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2022 | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.